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Abstract
Background: Data regarding the prevalence of metallo-β-lactamases (MBLs) among Pseudomonas aeruginosa
isolates in cystic fibrosis patients are scarce. Furthermore, there is limited knowledge on the effect of MBL
production on patient outcomes. Here we describe a fatal respiratory infection due to P. aeruginosa producing VIM-
type MBLs in a lung transplant recipient and the results of the subsequent epidemiological investigation.
Case presentation: P. aeruginosa isolates collected in the index patient and among patients temporally or spatially
linked with the index patient were analyzed in terms of antibiotic susceptibility profile and MBL production. Whole-
genome sequencing and phylogenetic reconstruction were also performed for all P. aeruginosa isolates producing
VIM-type MBLs. A VIM-producing P. aeruginosa strain was identified in a lung biopsy of a lung transplant recipient
with cystic fibrosis. The strain was VIM-1-producer and belonged to the ST308. Despite aggressive treatment, the
transplant patient succumbed to the pulmonary infection due to the ST308 strain. A VIM-producing P. aeruginosa
strain was also collected from the respiratory samples of a different cystic fibrosis patient attending the same cystic
fibrosis center. This isolate harbored the blaVIM-2 gene and belonged to the clone ST175. This patient did not
experience an adverse outcome.
Conclusions: This is the first description of a fatal infection due to P. aeruginosa producing VIM-type MBLs in a lung
transplant recipient. The circulation of P. aeruginosa isolates harboring MBLs pose a substantial risk to the cystic
fibrosis population due to the limited therapeutic options available and their spreading potential.
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Background
Pseudomonas aeruginosa is a non-glucose fermenter
Gram-negative rod, frequently encountered in the respira-
tory tract of cystic fibrosis patients. P. aeruginosa is char-
acterized by a low natural antimicrobial susceptibility and
by an outstanding ability for selecting and spreading anti-
microbial resistance in vivo [1, 2].
In 2018 the European Centre for Disease Prevention
and Control (ECDC) reported that 19.2% of the P. aeru-
ginosa invasive isolates tested were resistant to two or
more antimicrobial groups [3]. Higher rates of multi-
drug resistance were found in the cystic fibrosis popula-
tion; when P. aeruginosa isolates collected from cystic fi-
brosis patients in Northern Europe over the period
2006–2012 were analysed, multi-drug resistance was de-
tected in 61.4% of the isolates [4]. Carbapenem resist-
ance was reported by ECDC in 17.2% of the strains
tested, with large inter-country variations (0.0% in
Iceland, 15.8% in Italy, and 55.1% in Romania) [3].
Carbapenem resistance in P. aeruginosa is mediated by
several mechanisms including: i) intrinsic P. aeruginosa
resistance, such as the expression of inducible AmpC
cephalosporinase, which is associated with a reduced
susceptibility to imipenem [5]; ii) acquired resistance
through chromosomal gene mutations, such as the mu-
tational inactivation or downregulation of the OprD
porin, which drives imipenem resistance and decreases
meropenem susceptibility. In addition, the overexpres-
sion of efflux pumps of P. aeruginosa plays a major role
in mutation-driven resistance [6]; iii) horizontally ac-
quired resistance, such as genes encoding carbapene-
mases. These genes are typically located in class 1
integrons inserted into transposable elements. Among
carbapenemases, metallo-β-lactamases (MBLs) are the
most prevalent in P. aeruginosa. While at least nine dif-
ferent types of acquired MBLs have been described, the
VIM-type is among the most important for geographic
dissemination [7]. Furthermore, the VIM-type has
broader substrate specificities and a higher affinity for
carbapenems compared to other MBLs [8].
Carbapenemase production, and specifically MBL pro-
duction, is rarely documented in patients with cystic fi-
brosis. Mustafa and collaborators did not detect any
carbapenemase production when analyzing P. aeruginosa
isolates collected from cystic fibrosis patients in North-
ern Europe [4]. Furthermore, the impact of P. aeruginosa
antimicrobial resistance on the outcome of lung trans-
plant in cystic fibrosis patients is still controversial [9].
To the best of our knowledge, four cases of MBLs detec-
tion in cystic fibrosis patients have been reported in the
literature. Of these, only two reported outcome informa-
tion and none were characterized by an adverse outcome
[10–13]. Here we describe a fatal infection due to VIM-
1- producing P. aeruginosa in a cystic fibrosis patient
following lung transplantation. We also detail the epi-
demiological investigation performed in our medical
center after the isolation of P. aeruginosa producing
VIM-type MBLs.
Case presentation
Methods
P. aeruginosa isolates collected in the index patient and
among patients linked with the index patient were ana-
lyzed. The analysis involved the following steps: i) identi-
fication of bacterial isolates and susceptibility profile; ii)
detection of carbapenemase activity; iii) whole genome
sequencing (WGS) and phylogenetic analysis. Details
can be found in the Supplementary Materials.
Case description
A 29 year-old female with end-stage cystic fibrosis lung
disease (FEV1 21%, lung allocation score 47.6) under-
went bilateral orthotopic lung transplant in 2018. Pre-
transplant respiratory cultures were positive for
extensively-drug resistant mucoid and non-mucoid P.
aeruginosa with reduced susceptibility to carbapenems.
She was exposed to carbapenems approximately 12
months prior to transplant. On day 7 after transplant
the patient developed a right pleural empyema, requiring
a thoracic drainage and broad-spectrum antimicrobial
therapy (amikacin and ceftazidime). Respiratory cultures
collected on the same day grew extensively-drug resist-
ant mucoid P. aeruginosa (isolate SK76). SK76 showed a
reduced susceptibility to meropenem but results were
negative for carbapenemase production (Table 1). On
day 34, due to worsening clinical conditions and pro-
gression of the infection in the right pleural cavity, the
patient was transferred to the intensive care unit (ICU)
and a right pneumonectomy was performed. Lung bi-
opsy cultures collected on day 34 grew extensively-drug
resistant P. aeruginosa, resistant to carbapenems (isolate
SK77). Resistance to carbapenems was mediated by the
production of blaVIM-1 carbapenemase (Fig. 1). Despite
aggressive antimicrobial treatment (levofloxacin, high-
dose colistin and high-dose extended-infusion merope-
nem) and invasive life-support measures (venous-venous
extracorporeal membrane oxygenation and continuous
renal replacement therapy), the patient died on day 56.
Whole genome sequencing (WGS) analysis showed
that isolates SK76 and SK77 belonged to two different
and unrelated Sequence Types (STs): ST253 and ST308,
respectively (Fig. 2). Furthermore, SK76 and SK77 har-
bored a different resistance genes content. SK76 was
characterized by the following resistance determinants:
aadA7, aac(6′)-Ib7, blaPDC-9, blaOXA-488, blaOXA-
20, sul1, and gyrA. On the contrary, the following resist-
ance genes were detected in SK77: blaVIM-1, aadA7,
blaPDC-7, blaPER-1, blaOXA-488, and sul1 (Fig. 1).
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The detection of VIM-type MBLs among a cystic fi-
brosis patient prompted an epidemiological investiga-
tion in our medical center. All the respiratory
cultures of patients attending the adult and pediatric
cystic fibrosis center in 2018 were screened for the
presence of MBLs. Similarly, all the patients admitted
to the intensive care unit at the same time the index
patient was admitted were screened for the presence
of MBLs-producing isolates. A blaVIM-2 P. aerugi-
nosa isolate was detected in the respiratory cultures
of a male patient admitted to our adult cystic fibrosis
center in 2018 for fever and worsening respiratory
function (isolate SK78). The past medical history of
this patient was characterized by: i) chronic
colonization with methicillin-susceptible Staphylococ-
cus aureus, mucoid and non-mucoid P. aeruginosa; ii)
three respiratory exacerbations requiring treatment
with carbapenems in the 12 months prior to the isola-
tion of SK78; iii) end-stage lung disease (FEV1 27%).
After the isolation of SK78, the patient was treated
with high-dose extended-infusion meropenem and
amikacin, without any reported adverse effects. Anti-
microbial treatment led to fever remission and global
clinical improvement. Twelve months after the isola-
tion of SK78, the patient was still alive with a stable,
although severe, pulmonary function (FEV1 27%). Iso-
late SK78 was characterized by a reduced susceptibil-
ity to meropenem and by the following additional
resistance genes: aac(6′)-Ib7, blaOXA-50, and gyrA
(Table 1 and Fig. 1). SK78 belonged to the epidemic
high-risk clone ST175 (Fig. 2). No other MBLs-
producing isolates were identified by our epidemio-
logical investigation.
Discussion and conclusions
To the best of our knowledge, this is the first description
of a fatal infection due to P. aeruginosa producing VIM-
type MBLs in a cystic fibrosis lung transplant recipient.
Among the four cases of MBLs-producing P. aeruginosa
infections in cystic fibrosis patients already available in
the literature, only two reported outcome data and only
one involved a transplant recipient [10–13].
Our description highlights several substantial issues.
First, the broad spectrum of resistance of P. aeruginosa
isolates producing MBLs and the limited therapeutic op-
tions available for their treatment. Second, the virulence
of P. aeruginosa isolates producing MBLs and their impact
on the patient outcomes. Third, the spreading potential of
P. aeruginosa isolates producing MBLs. Fourth, the need
for stringent and efficient antimicrobial stewardship and
infection control policies in cystic fibrosis centers.
Broad spectrum of resistance of P. aeruginosa isolates
producing MBLs and limited therapeutic options available
for their treatment
The broad spectrum of resistance of P. aeruginosa isolates
producing MBLs restricts therapeutic options to few mole-
cules, such as colistin, fosfomycin, aztreonam, and cefidero-
col [7]. Of these, cefiderocol is not yet clinically available.
Furthermore, some of these molecules (e.g. colistin) are
Table 1 Antimicrobial susceptibility profiles of the P. aeruginosa isolates SK76, SK77, and SK78
SK76 SK77 SK78
MIC (mcg / ml) MIC (mcg / ml) MIC (mcg / ml)
Amikacin 16 I > 16 R 16 I
Gentamicin > 4 R > 4 R > 4 R
Tobramycin > 4 R > 4 R > 4 R
Ciprofloxacin > 1 R 0.5 S > 1 R
Levofloxacin > 2 R 1 S > 2 R
Colistin < 2 S < 2 S < 2 S
Piperacillin/tazobactam < 8 S > 16 R > 16 R
Piperacillin < 8 S > 16 R > 16 R
Cefepime > 8 R > 8 R > 8 R
Ceftazidime 4 S > 32 R > 32 R
Ceftazidime/avibactam < 2 S > 8 R > 8 R
Ceftolozane/tazobactam < 1 S > 4 R > 4 R
Imipenem > 8 R > 8 R > 8 R
Meropenem 8 I 32 R 8 I
Fosfomycin > 128 R 16 S 16 S
Aztreonam < 1 S > 256 R > 256 R
VIM-type carbapenemase neg pos pos
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characterized by a narrow therapeutic window, which con-
tributes to the occurrence of drug-related adverse events. It
is also worth noting that the production of MBLs is typic-
ally associated with additional resistance mechanisms, as
shown by strain SK77 and SK78. For this reason, combin-
ation therapies are needed to contain infections due to
MBL-producing isolates. There is still no consensus on the
most appropriate antibiotic combinations to be used in the
setting of these difficult-to-treat infections [14].
Virulence of P. aeruginosa isolates producing MBLs and
their impact on the patient outcomes
The evaluation of the virulence of P. aeruginosa isolates
producing MBLs in comparison to the virulence of sen-
sitive P. aeruginosa strains is a hot topic [15, 16]. Acqui-
sition of resistance is thought to be linked with fitness
costs that decrease the virulence of multi-drug resistant
P. aeruginosa strains [17–20]. However, several studies
reported the presence of resistance mutations not associ-
ated with fitness costs and the development of compen-
satory or suppressor mutations in multi-drug resistant
strains. Compensatory and suppressor mutations allow
multi-drug resistant strains to regain their initial fitness,
so that, in the end they preserve their original virulence
[19, 21, 22]. Persoon and collaborators reviewed the
charts of 198 patients admitted at the Erasmus Medical
Center in Rotterdam (Netherlands) in the period 2008–
2016 and who had a culture positive for P. aeruginosa
producing blaVIM enzymes. P. aeruginosa producing
blaVIM enzymes isolates were strongly associated with
the death of 32 patients, leading to a 16.2% attributable
mortality [23]. While the infection with strain SK77
likely contributed to the death of our female patient, the
infection with strain SK78 did not substantially alter the
clinical course of our male patient. Whether the adverse
outcome of our female patient was mainly due to the
pathogenicity of the VIM-producing isolate or to the se-
vere pre-existing comorbidities of the host is difficult to
be ascertained.
Spreading potential of P. aeruginosa isolates producing
MBLs
MBLs are generally located on transposable genetic ele-
ments, which largely increases the spreading potential of
these strains. Furthermore, ST308 is a recently reported
emerging high-risk clone, while ST175 is among the
three major international high-risk extensively-drug re-
sistant clones and is widely distributed in several Euro-
pean countries [24]. Although isolates SK77 (ST308) and
SK78 (ST175) did not cause an outbreak in our medical
center, their spreading potential cannot be ignored. In
this setting, appropriate epidemiological investigations
and stringent infection control procedures are
mandatory.
Fig. 1 Heatmap of the resistance gene presence/absence of the
Pseudomonas aeruginosa isolates SK76, SK77, and SK78. The
antimicrobial gene family is shown on the first column on the left
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Need for stringent and efficient antimicrobial stewardship
and infection control policies in cystic fibrosis centers
The selective antimicrobial pressure promoted by broad-
spectrum agents favors the emergence of resistant
strains. Specifically, previous studies have shown an as-
sociation between the use of piperacillin/tazobactam,
quinolones, and cephalosporins and the emergence of
VIM-positive P. aeruginosa isolates [25]. Furthermore,
cystic fibrosis patients harboring MBLs in their respira-
tory tract may serve as hospital sources of carbapene-
mases. The acquisition of extensively-drug resistant P.
aeruginosa isolates, especially clonal isolates, is known to
be associated with increased pulmonary exacerbation
rate, exaggerated lung function decline, and progression
to end-stage lung disease [26]. For these reasons, segre-
gation of patients harboring MBLs and environmental
decontamination of areas where these patients transi-
tioned may be need in order to avoid the dissemination
of VIM-positive P. aeruginosa isolates in cystic fibrosis
centers [13].
Despite the relevance of the data presented, this study
has several limitations. We did not confirm the location
of the blaVIM genes in class 1 integrons in the bacterial
chromosome of the P. aeruginosa isolates evaluated.
Genes encoding carbapenemases are generally found in
class 1 integrons along with determinants of aminogly-
coside resistance. These integrons are often inserted into
transposable elements, which contributes to the spread-
ing potential of these strains. Furthermore, we did not
perform virulence studies. Our epidemiological investi-
gation was restricted to the year 2018: the circulation of
P. aeruginosa strains harboring MBLs in our medical
center before 2018 was not assessed. Finally, our epi-
demiological investigation was limited to patients: poten-
tial environmental sources of P. aeruginosa isolates
producing MBLs were not evaluated and the sources of
the isolates SK77 and SK78 were not identified.
In summary, we described the first fatal infection due
to P. aeruginosa producing VIM-type MBLs in a cystic
fibrosis lung transplant recipient. P. aeruginosa produ-
cing VIM-type MBLs represents a matter of concern be-
cause of the limited therapeutic options available and its
dissemination potential, especially in the setting of fra-
gile hosts, such as cystic fibrosis patients.
Fig. 2 Maximum likelihood phylogenetic tree including the three Pseudomonas aeruginosa isolates of the study (SK76, SK77 and SK78) and
background strains retrieved from the PATRIC database
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